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Abstract
In Jordan, Salvia ceratophylla L. is traditionally used in the treatment of cancer, microbial infections, and urinary disorders. 
This study aimed: (1) to chemically characterize S. ceratophylla essential oil (EO) from South Jordan, by gas chromatography 
(GC) and gas chromatography-mass spectrometry (GC–MS); and (2) to evaluate in vitro the cytotoxic, anti-inflammatory, 
and antiprotozoal activities of the EO, it’s predominant components, and the hexane (A), ethyl acetate (B), methanol (C) and 
crude-methanol extracts (D). The analysis revealed that the EO has 71 compounds, with linalool (54.8%) as main constitu-
ent. Only the hexane extract (A) showed some cytotoxic activity against SK-MEL, KB, BT-549, SK-OV-3, LLC-PK1 and 
VERO cells lines with  IC50 between 60 and > 100 µg/mL. The EO inhibited NO production  (IC50 90 µg/mL) and NF-κB 
activity  (IC50 38 µg/mL). The extracts A, B, and D inhibited NO production and NF- κB activity with  IC50 between 32 and 
150 µg/mL. Linalool considerably inhibited NO production  (IC50 18 µg/mL). The extracts tested did not exhibit antileish-
manial activity. Regarding antitrypanosomal activity, the EO exhibited significant results with  IC50 2.65 µg/mL. In conclu-
sion, Jordan S. ceratophylla EO represents a rich source of linalool and bears a promising therapeutic potential for further 
antitrypanosomal drug development.
Keywords Lamiaceae · Essential oil · Chemical composition · Cytotoxicity · Anti-inflammatory activity · Neglected 
diseases
1 Introduction
Salvia ceratophylla L. (Arabic: Lusan Al-haea, English: 
horn-leaved sage) is a biennial lemon-scented herb and one 
of the 19 indigenous Salvia species native in Jordan [1]. 
This species grows in diverse Jordanian geographic areas, 
such as Mafraq, Ajlun, Ma’an, Tafila and Dana [1] and Wadi 
Musa [2]. It is also found in several Asian-temperate regions, 
including Caucasus, Transcaucasus, Middle Asia (Turk-
menistan), and Near East (Afghanistan, Iran, Iraq, Lebanon, 
Syria, Palestine, Israel, and Turkey) [3, 4].
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S. ceratophylla is used in traditional medicine of the Mid-
dle East against various ailments, e.g. inflammation, fungal, 
and nociceptive diseases [4–6]. In Middle Eastern countries 
such as Jordan, Lebanon, and Syria, the herbalists prescribe 
Salvia species as boiled tea to relieve abdominal pain, head-
aches, stomachaches, and to treat cancer, microbial infec-
tions, asthma, coughs and other pulmonary and urinary 
disorders [7]. It is also recommended in folk medicine to 
disinfect homes after sickness [8]. Several Salvia species and 
their essential oils are used in various traditional medicines 
to treat malaria [9, 10] and leishmaniasis [11].
Despite the composition of S. ceratophylla essential oil 
(EO) grown in various habitats of the Near East countries 
has been analyzed and a wide variation in their composition 
has been reported [3, 12–14], there is only one report on 
the composition of S. ceratophylla EO originated from the 
middle of Jordan [15].
Few reports showed the biological activities of S. cera-
tophylla extracts from various locations in the Middle East. 
Some S. ceratophylla extracts revealed cytotoxic activity 
against some types of cancer cell lines [16, 17].
The antioxidant activity of S. ceratophylla originated 
from Turkey and Iran has been assessed by different meth-
ods. Gürsoy et al. [3] showed the antioxidant activity of 
essential oil of S. palaestina and S. ceratophylla from Tur-
key. The S. ceratophylla chloroform extract inhibited the 
activity of butyrylcholine esterase [18]. Among 9 Salvia spe-
cies from Iran, the methanolic extract of S. glutinosa and 
S. ceratophylla revealed the strongest antioxidant activity 
[17]. The anti-inflammatory activity of the EO from Salvia 
species is mediated by the inhibition of nitric oxide (NO) 
production and nuclear kappa B (NF-κB) activation [10]. 
Linalool and linalyl acetate, the major volatile constituents 
of the EO of several aromatic plants exhibit in vivo strong 
anti-inflammatory activity against Carrageenin-induced 
edema [19].
The extracts and EO of some other Salvia species showed 
antiprotozoal activity against malaria, leishmaniasis and 
human African trypanosomiasis [20–22]. The hydroalco-
holic extract of S. officinalis from Algeria completely inhib-
ited the growth of Leishmania major [23]. Furthermore, 
linalool exhibited antileishmanial activity in a concentra-
tion-dependent fashion [24, 25]. Caryophyllene showed 
anti-protozoal activity against Leishmania donovani [26] 
and Trypanosoma brucei [27].
Only a few studies reported the biological activities of 
S. ceratophylla from Jordan. However, the anti-inflamma-
tory activity of hexane, ethyl acetate and methanol extracts 
obtained from the aerial parts of Jordanian Salvia species 
have been evaluated by inhibition of croton oil-induced 
mouse ear edema [6]. Kasabri et al. [5] studied the inhibitory 
activity of the aqueous extracts of S. ceratophylla and other 
Salvia species grown in Jordan against pancreatic triacylg-
lycerol lipase, α-amylase and α-glucosidase. S. ceratophylla 
exhibited cytotoxic efficacy against CaCo2 cells with an  IC50 
value of 9.2 ± 0.5 μg/mL.
However, there is limited information about the chemi-
cal composition and biological activities of medicinal plants 
from Jordan flora. No studies have been carried out yet on S. 
ceratophylla EO from Dana Biosphere Reserve in southern 
Jordan and to the best of our knowledge, there are no previ-
ous reports on the antiprotozoal activity of this plant. Thus, 
the aim of this work was to evaluate for the first time the 
chemical composition of S. ceratophylla EO grown in Dana 
Biosphere Reserve (Southern Jordan), as well as, to assess 
the cytotoxic, antileishmanial, and antimalarial activities of 
its essential oil and other extracts.
2  Materials and Methods
2.1  Plant Material
Aerial parts of S. ceratophylla were collect during the spring 
season, throughout Dana Biosphere Reserve (South of Jor-
dan). The voucher specimens were identified by Mr. Hatem 
Taifour (Researcher at School of GeoSciences, University of 
Edinburgh Edinburgh EH9 3FF, U.K.) and were deposited 
in the Herbarium of Shoubak University College, Al-Balqa 
Applied University, Jordan under the number #0009- Sc-
DSh-2015 and in the Herbarium of National Center for 
Natural Products Research, School of Pharmacy, University 
of Mississippi, USA under the number #18,330. The plant 
material for extraction was air dried and crushed into small 
pieces with a hammer mill before extraction.
2.2  Isolation of Extracts
2.2.1  Isolation of Essential Oil
To isolate EO, the crushed aerial parts of S. ceratophylla 
were hydro distillated during 3 h with a Clevenger-type 
apparatus, according to the European Pharmacopoeia [28]. 
The oil obtained was dried over anhydrous sodium sulphate 
and kept at 4 ºC until analyzed and tested.
2.2.2  Extraction of Non‑polar and Polar Extracts
The hexane, ethyl acetate, and methanol extracts from the 
crude areal parts of S. ceratophylla were obtain as follows: 
powdered plant material (600 g) was soaked with hexane 
followed by ethyl acetate, and then methanol for 48 h for 
each solvent in ratio of 500 mL per 100 g. The process of 
extraction for each solvent was repeat several times to ensure 
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complete extraction of the compounds. The obtained extracts 
for each solvent were combine together and subject to rotary 
evaporation at 40 °C. The evaporation led to dry hexane (A), 
ethyl acetate (B), and methanol (C) extracts with yields of 
4.21%, 1.77% and 6.93%, respectively.
2.2.3  Extraction of Crude Methanol Extract
A sample of 50 g of powder plant materials was soaked in 
250 mL of methanol for 48 h. The process of extraction 
was repeat several times to ensure complete extraction of 
the compounds. The obtained methanol extracts were filter 
combined and subject to rotary evaporation at 40 °C. The 
obtained crude methanol dry extract (D) yielded 18.96%. 
All extracts (A-D) were freeze-dry and stored at 4 °C for 
further analyses.
2.3  Chemical Composition
2.3.1  Chemicals
GC-grade n-hexane (> 99%) and the reference standards 
were purchased from Sigma-Aldrich or isolated in the 
National Center for Natural Products Research, University 
of Mississippi. A mixture of n-alkanes  (C8H18–C23H48) was 
use in the determination of retention indices and were pur-
chased from PolyScience Corp.
2.3.2  Gas Chromatography‑Mass Spectrometry (GC–MS)
Gas chromatography analysis was performed in an Agi-
lent 7890B GC equipped with a 5975C quadruple mass 
spectrometer and a 7693-auto sampler. Separation was 
achieve using an Agilent J&W HP-1 (100% dimethyl-pol-
ysiloxane) fused silica capillary column (60 m × 0.25 mm 
I.D. × 0.25 µM film thickness). Helium was the carrier gas 
at a constant flow rate of 1.5 mL/min. Oven temperature 
program: 50 °C hold for 2 min, after 50–170 °C at 2 °C/
min, 170–250 °C at 6 °C/min (hold 10 min). The injector 
temperature was 250 °C, the injection volume was 0.5 µL 
and a split ratio of 50:1. The EO was diluted in n-hexane 
(0.5% v/v) prior to GC/MS analysis.
Mass spectra were record at 70 eV at a scan mode from 
m/z 40 to 500. The transfer line and the ion source tempera-
tures were 260 °C and 230 °C, respectively. Data acquisition 
was made with Agilent MSD Chemstation (F.01.03.2357).
2.3.3  Identification of Individual Components
Compound identification was carried out through com-
parison of the spectra with the database (Wiley and NIST) 
using a probability-based matching algorithm. Further 
identification was based on the relative retention indices 
compared with reference standards and literature data [29].
2.4  Cytotoxic activity
All cell lines used in this study were purchase from Ameri-
can Type Culture Collection (ATCC, Rockville, MD). 
The cytotoxic activity of the EO, extracts isolated from S. 
ceratophylla and pure compounds was determined in vitro 
against various human cancer cells: skin malignant mela-
noma (SK-MEL), human KB carcinoma (KB), breast ductal 
carcinoma (BT-549), ovarian carcinoma (SK-OV-3), and in 
two non-cancerous mammalian kidney cell lines (LLC-PK1 
and VERO).
Cells were seed at a density of 25,000 cells/well and incu-
bated during 24 h. The tested EO, extracts and pure com-
pounds were added separately at studied concentrations and 
cells were re-incubated during 48 h. After incubation time, 
the viability of cells was assessed by using Neutral Red Dye 
as described [30]. DMSO was use as negative control and 
doxorubicin as positive control.
2.5  Anti‑inflammatory Activity
2.5.1  Inhibition of Cellular Oxidative Stress Assay
The cellular antioxidant activity of S. ceratophylla EO and 
other extracts was measured in human HepG2 hepatoma 
cells This assay determines the ability of test samples to pre-
vent intracellular generation of peroxyl radicals in response 
to 2,2- azobis (2-amidinopropane) dihydrochloride (ABAP, 
Sigma-Aldrich, St Louis, MO, USA).
HepG2 cells were culture in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), 50 units/mL penicillin and 50 µg/mL strepto-
mycin. Cells were seed in 96-well plates (60,000 cells/well) 
and incubated for 24 h. The tested samples were diluted 
in serum free medium containing 25 µM  2′,7′, dichoro-
flouresceine diacetate (DCFH-DA, Invitrogen, Carlsbad, 
CA, USA). The cells were wash with PBS and treated with 
test samples during 1 h. The medium containing tested 
samples was removed, ABAP (600 µM) was added and 
the plate was immediately placed on a Spectra Max plate 
reader for kinetic reading every 5 min during 1 h (37 ºC, 
emission at 538 nm and excitation at 485 nm). Quercetin 
(Sigma-Aldrich) was use as positive control. To calculate 
the percentage of decrease in oxidative stress, the Area 
Under the Curve (AUC) of fluorescence versus time was 
used.
Decrease in oxidative stress (%)
= AUC control100− [AUC tested sample×100]
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2.5.2  Nitric Oxide (NO) Measurement
The NO inhibition by EO, extracts of S. ceratophylla and 
pure compounds, was assess by the following methodol-
ogy [31]. Briefly, mouse macrophage cells (RAW 264.7) 
were culture in phenol red free RPMI medium with 10% 
bovine calf serum and 100 U/mL penicillin and 100 µg/mL 
streptomycin.
Cells were seed in 96-well plates (50,000 cells/well) and 
incubated during 24 h. The tested samples were dilute in 
serum free medium, incubated during 30 min, then lipopoly-
saccharide (LPS, 5 µg/mL) was added and cells were incu-
bated for further 24 h. The level of nitrite in the cell super-
natant was measure by using Griess reagent. The inhibition 
of nitrite production by the tested samples was calculate in 
comparison to the vehicle control. Parthenolide (Sigma-
Aldrich) was use as positive control.  IC50 values were obtain 
from dose curves.
2.5.3  Assay for Inhibition of NF‑κB Activity
The inhibition activity of tested samples against NF-κB was 
evaluate as described [31]. The SW 1353 human chondro-
sarcoma cell line was culture in a mixture of Dulbecco’s 
Modified Eagle’s Medium (DMEM) and Ham’s F-12 Nutri-
ent (DMEM/F12) supplemented with 10% FBS, 100 U/Ml 
penicillin and 100 µg/mL streptomycin. Cultured cells were 
washed in antibiotic and FBS-free DMEM/F12 medium and 
then re-suspended in FBS-free DMEM/F12 medium con-
taining 2.5% FBS. NF-κB luciferase plasmid construct was 
added to the cell suspension in a concentration of 50 µg/
mL and incubated for 5 min at 25ºC. The cells were trans-
fected by electroporation at 160 V and one 70 ms pulse 
using BTX disposable cuvettes (model 640 in a BTX Elec-
tro Square Porator T 820—BTX I, San Diego, CA, USA), 
Transfected cells were plate in 96-well plates at a density of 
1.25 × 105cells per well in 200 µL of DMEM/F12 contain-
ing 10% FBS and antibiotics. After incubation for 24 h, the 
cells were treated with test samples for 30 min and then 
induced with PMA (70 ng/mL) for 8 h. The inhibition of 
NF-κB activity by EO, other extracts, and pure compounds 
was calculated in comparison to vehicle control. The  IC50 
values were obtain from the dose curves. Parthenolide was 
use as positive control.
2.6  Antileishmanial and Antitrypanosomal 
Activities
2.6.1  Sample Preparation
EO and extracts (A-D) at a stock concentration of 20 mg/mL 
were dilute to 4 mg/mL with DMSO. The obtained solutions 
(4 mg/mL) were four-fold diluted with incomplete RPMI 
medium to 1 mg/mL. Pure compounds at a stock concen-
tration of 2 mg/mL in DMSO were diluted four-fold with 
incomplete RPMI medium to 0.5 mg/mL.
2.6.2  In Vitro Antileishmanial and Antitrypanosomal 
Assays
The extracts and pure compounds (highest concentrations 
20 µg/mL for extracts and 10 µg/mL for pure compounds) 
were subject to different tests, namely Leishmania donovani 
promastigote assay, L. donovani axenic amastigote assay, 
L. donovani THP1 macrophage amastigote assay, Trypano-
soma brucei trypamastigotes assay and THP1 toxicity assay. 
Alamar Blue assay was perform as previously described by 
other authors [32, 33].
These assays have been adapted to 384-well micro-plate 
format. A 3–4 days old culture of Leishmania donovani pro-
mastigotes harvested in the exponential growth phase was 
diluted with RPMI medium to 1 × 106 cells/mL for promas-
tigote assays. A 3–4 days old culture of Leishmania dono-
vani axenic amastigotes was diluted with RPMI medium to 
2 × 106 cells/mL for axenic amastigote assays. A 2 days old 
culture of Trypanosoma brucei harvested in the exponen-
tial phase was diluted with Iscove’s Modified Dulbecco’s 
Medium (IMDM) to 5 × 103 cells/mL for the antitrypano-
somal assay.
Samples were added to the L. donovani promastigotes, L. 
donovani axenic amastigotes or T. brucei trypamastigotes 
cultures. The extracts were initially test at single concentra-
tions of 20 mg/mL for primary screening. The active extracts 
and pure compounds were test at three or six concentrations 
ranging from 10 to 0.0032 µg/mL. The plates were incubated 
at 26 °C for 72 h (37 °C for axenic amastigotes and T. brucei 
trypamastigotes) and growth of cultured parasites was deter-
mined by the Alamar Blue assay [32 33].
The extracts and single compounds were also test against 
L. donovani intracellular amastigotes in THP1 cells employ-
ing a recently developed parasite-rescue and transformation 
assay [15].
2.7  THP1 Toxicity Assay and Macrophage 
Amastigote Assay
A 4 days old THP1 cell culture harvested in the exponential 
growth phase was diluted with RPMI medium to 2.5 × 105 
cells/mL. PMA was added to a final concentration of 25 ng/
mL. A PMA treated culture was dispense in experimental 
culture plates and incubated overnight at 37 °C in a 5%  CO2 
incubator. The plates with differentiated THP1 cells were 
wash with serum-free medium. For THP1 toxicity assay, 
the diluted test samples (extracts or pure compounds) were 
add over differentiated THP1 cells and plates were incu-
bated during 48 h at 37 °C in a 5%  CO2 incubator. Cell 
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growth was determined by the Alamar Blue assay.  IC50 and 
 IC90 values were calculate from dose response curves using 
XLFit® [32].
3  Results and Discussion
3.1  Essential Oil Composition
In this study, the yield (0.34 ± 0.001%) of S. ceratophylla EO 
was higher than in other studies performed in the middle of 
Jordan, where the yield was 0.1% [15]. It is also lower than 
those grown in Turkey with a yield of 0.4% [13] and 0.8% 
[3] and in Iran (0.6%, [12]). Usually, the yield variation of S. 
ceratophylla EO is relate to the influence of environmental 
factors linked to predominant climatic and geographical dif-
ferences in various growth areas [34, 35].
The EO was analyzed by GC and GC/MS, the identi-
fied components and their relative percentages are listed in 
Table 1. Seventy-one components were identified, repre-
senting 93.5% of the total constituents (Table 1). The major 
compounds of the EO were linalool (54.8%), germacrene-D 
(6.4%), bicyclogermacrene (5%) and the bicyclic diterpene 
alcoholsclareol (4.3%). As far as we know, there is no previ-
ous report on the S. ceratophylla EO composition originated 
from Dana Biosphere Reserve (Southern Jordan). However, 
there are some works reporting the chemical composition 
of S. ceratophylla originated from middle of Jordan [15], 
Turkey [3, 13, 14] and Iran [12].
The EO of the dried flowers of S. ceratophylla grown in 
the middle of Jordan was dominate by oxygenated monoter-
penes (58.28%) (Al Jaber, 2016). S. ceratophylla oil grown 
in Elazığ, Turkey is characterized by a high amount of ger-
macrene D (27.4%) [13].
Gürsoy et al. [3] also reported that the composition of 
S. ceratophylla EO grown in Turkey, was dominated by 
γ-muurolene (11.4%) and α-pinene (7.6%) as major com-
pounds. Furthermore, the oils of S. ceratophylla grown 
in Kayseri, Elazığ and Adıyaman, Turkey were analyzed: 
α-Pinene (27.0%), β-pinene (16.3%) and β-caryophyllene 
(10.6%) were the major components in the Kayseri sam-
ple, α-pinene (24.6%) and β-pinene (10.3%) in the Elazığ 
samples, α-pinene (23.7%), 1,8-cineole (8.9%) and bor-
neol (7.0%) in the Adıyaman sample. The S. ceratophylla 
EO from Iran was dominated by cis-thujopsene (10.9%), 
cyclopentadecanolide (6.1%), methyl linoleate (4.5%) and 
α-humulene (3.6%) [12].
Our results revealed that S. ceratophylla EO, originated 
from southern Jordan showed significant differences com-
pared with the oils obtained from samples grown in other 
locations and was distinguished by its high concentration 
of linalool. Our results also showed that this EO is distinct 
by containing the bicyclic diterpene alcohol sclareol, while 
Table 1  Composition of Salvia ceratophylla L. essential oil from 
Dana Biosphere Reserve, South Jordan







1045 trans-Linalool oxide 0.2







1224 Linalyl acetate 0.2
1319 δ-Elemene 0.4
1331 Neryl acetate 0.2
1333 α-Cubebene 0.1





























1575 Caryophyllene oxide 0.5
1580 Globulol 0.5
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this compound was absent in S. ceratophylla from Middle 
Jordan [35], Turkey [3, 13, 14] and Iran [12]. This variation 
might be ascribed to the influence of various factors such 
as seasonal variation and some environmental conditions 
such as climate, heavy metals pollution and type of soil, in 
which the plants were grown [35, 36]. Furthermore, har-
vesting time, temperature and drying period of plants, may 
also influence the yield of the EO and their phytochemical 
composition, because these factors are known to increase the 
concentration of some aromatic oil components, especially 
linalool [37]. Kumar et al. [38] reported higher contents of 
linalool in S. sclarea under high daily light exposure, while 
the highest content of germacrene D and sclareol required 
50% and 75% of shade, respectively.
Moreover, the EO of other Salvia species grown in Jordan 
were dominate by linalool as major component. Linalool was 
the major component in the oils of fresh and dry aerial parts 
of S. dominica (31.4% and 18.3%, respectively) [39]. The 
main compound of EO extracted from fresh S. verbenaca 
was mainly linalool [40].
3.2  Cytotoxic Activity Against Cancer Cells
The cytotoxic activity of S. ceratophylla EO and other 
extracts against cancer and non-cancer cell lines is summa-
rize in Table 2. To the best of our knowledge, the cytotoxic 
activity of S. ceratophylla EO is reporting here for the first 
time. The EO (up to a concentration of 100 µg/mL), linalool 
and other tested pure compounds (up to a concentration of 
10 µg/mL) did not exhibit cytotoxic activities against all 
cell lines tested. In agreement with our results, other reports 
showed that linalool did not exhibit cytotoxic activity up to a 
concentration of 200 μg/mL against several cancer cell lines 
[41]. Nevertheless, linalool had significant cytotoxic activ-
ity against various cancer cell lines, such as BCC-1/KMC, 
AGS, RTCC-1/KMC, U2OS, HeLa, H520, H661, OSCC-1/
Compounds listed in order to their elution on the HP-1 column
RRI Relative retention indices calculated against  C8 –  C23n-alkanes 
on the apolar HP-1 column
% calculated from GC/MS data
Table 1  (continued)













1658 Aromadendrene oxide 0.3
1661 α-Cadinol 1.0
1679 Isoaromadendrene epoxide 0.1
1688 Ledene oxide 0.1
1707 Shyobunol 0.4
1727 8-Hydroxylinalool 0.1





Table 2  Cytotoxic activity  (IC50) of S. ceratophylla EO, polar and non-polar extracts and pure compounds
NA not active at 10 µg/mL for tested pure compound, and at 100 µg/mL for tested extracts
Sample code Cancer cell lines Kidney epithelial Kidney fibroblast
SK-MEL KB BT-549 SK-OV-3 LLC-PK1 Vero
IC50 IC50 IC50 IC50 IC50 IC50
µg/mL µg/mL µg/mL µg/mL µg/mL µg/mL
EO NA NA NA NA NA NA
A 95 70 70 100 60  > 100
B  > 100 NA  > 100 NA NA NA
C NA NA NA NA NA NA
D NA NA NA NA NA NA
Linalool NA NA NA NA NA NA
(-)trans-Caryophyllene NA NA NA NA NA NA
α-Terpineol NA NA NA NA NA NA
Doxorubicin 0.8 1.4 0.85 2 1.2  > 5
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KMC, J82 [42]. Furthermore, it enhanced the cytotoxic 
activity of doxorubicin against doxorubicin-resistant MCF-7 
breast cancer cells [43].
In addition, among all S. ceratophylla polar and nonpo-
lar extracts tested, the hexane extract (A) exhibited slight 
cytotoxic activity against all tested cancer cell lines. The 
 IC50 values of A extract against SK-MEL, KB, BT-549, 
SK-OV-3, LLC-PK1 and VERO cells were 95, 70, 70, 100, 
60, and > 100 µg/mL, respectively.
However, our results are in agreement with other previ-
ous reports. Abu-Dahab et al. [16] showed that 70% ethanol 
extract of S. ceratophylla originated from Middle Jordan, 
exhibited low cytotoxic activity against several cancer cell 
lines. Furthermore, compared with other Salvia species from 
Jordan, the cytotoxic activity of S. ceratophylla 70% ethanol 
extract tested by using the sulforhodamine B colorimetric 
assay was comparable or even higher against the obesity-
related HCT116 and Caco2 colorectal carcinoma cell lines. 
The cytotoxic activity of S. ceratophylla against other obe-
sity-related colorectal cell lines including HT29, SW620, 
and PDL was low, but higher than other Salvia species tested 
[5, 17] demonstrated that among various species of Salvia, S. 
ceratophylla methanol extract exhibited the strongest activ-
ity against human amelanotic melanoma (C32, CRL1585), 
and renal cell adenocarcinoma (ACHN, CRL1611) with  IC50 
values of 20.8 and 27.2 μg/mL, respectively.
However, the variation in the cytotoxic activity of Salvia 
species may be due to the variation in their chemical com-
position, which can be influence by various factors such as 
chemotype and environment [4]. It was also reported that the 
cytotoxic activity of S.officinalis was affect by solvents used 
to obtain various extracts with various yields and quality of 
secondary metabolites [44].
3.3  Inhibition of Oxidative Stress 
and Anti‑Inflammatory Activity
Nitric oxide (NO) is a free radical and its production at high 
levels was associated with inflammation and cancer. The 
metabolic pathway, which is known as the L-arginine: NO 
pathway is the main source for NO production in mamma-
lian cells by a group of enzymes known as the nitric oxide 
synthases (NOS). Inducible NOS (iNOS; NOS2; or type 
II NOS) is the enzyme responsible for the involvement of 
NO in inflammatory processes. Accordingly, the inhibi-
tion of NO production has been considered as a potential 
anti-inflammatory and cancer chemo-preventive strategy 
[45]. On the other hand, the activation of NF-κB represents 
a mechanistic connection between chronic inflammation 
and tumorigenesis [46]. The Specificity Protein 1 (Sp1) is 
a transcription factor, which binds GC/GT-rich promoter 
elements through three C2H2-type zinc fingers that are pre-
sent in their C-terminal domains [47]. Sp1 plays a major 
role in regulating the expression of genes involved in cell 
differentiation, cell cycle and apoptosis [48]. As compared 
with normal tissues, the activity and / or expression levels 
of Sp 1 were increased in some tumors such as carcinomas 
of breast [49], thyroid [50], and pancreas [51]. Sp1 plays an 
important regulatory role in controlling pathways of tumor 
development and progression. Thus, it may be an attractive 
therapeutic target for anticancer natural agents.
The EO of several Salvia species were being report to 
inhibit iNOS [52]. Therefore, we also evaluated, for the first 
time, the in vitro inhibiting intracellular oxidative stress 
activity of the EO and polar and nonpolar extracts S. cera-
tophylla from southern Jordan.
With exception of the EO, which did not decrease the 
oxidative stress, our results revealed that all other extracts 
exhibited antioxidant activity by inhibiting intracellular oxi-
dative stress (Table 3). The hexane (A) and ethyl acetate 
(B) extracts were the most active in decreasing oxidative 
stress. At the concentration 1000 µg/mL the decrease by the 
extracts was 50 and 47%, respectively, while at the concen-
tration 500 µg/mL the decrease by the extracts was 56 and 
25%, respectively. Among all tested pure compounds, only 
caryophyllene showed weak activity in decreasing oxidative 
stress by 35 and 31% at concentrations of 500 and 250 µg/
mL, respectively.
The EO showed the lowest inhibition in NO production 
with an  IC50 90 µg/mL and the highest inhibition activity 
against NF-κB with an  IC50 38 µg/mL. At the same time, 
it did not inhibit the transcription factor Sp-1. The extracts 
A, B and D inhibited NO production and NF- κB with  IC50 
values of 32, 30, and 40 µg/mL, and 70, 85 and 150 µg/mL, 
respectively. The two non-polar extracts (hexane and ethyl 
acetate, A and B) of S. ceratophylla, inhibited Sp-1 with  IC50 
values of 70 and 160 µg/mL, respectively.
Linalool was the only pure compound showing high and 
significant NO inhibition with an  IC50 value of 18 µg/mL. 
Linalool, caryophyllene and α-terpineol inhibited NF-κB 
activity with  IC50 values of 60, 45 and 100 µg/mL, respec-
tively. Caryophyllene was the only pure compound, which 
inhibited Sp-1 with an  IC50 value of 48 µg/mL.
The antioxidant activity of S. ceratophylla EO measured 
by different methods was moderate and slightly lower than 
the activity of S. palaestina essential oil [3]. Moreover, S. 
officinalis EO from Jordan showed anti-inflammatory effects 
and significantly inhibited NO production stimulated by LPS 
in macrophages, without affecting cell viability, in concen-
trations up to 0.64 μL/mL [53].
Nevertheless, the anti-inflammatory activity assessed by 
edema reduction was observed for S. ceratophylla ethylac-
etate extract with an  ID50 98 μg/cm2 compared with indo-
methacin, the hexane and methanol extract showed very low 
activity with an  ID50 of > 300 μg/cm2 [6]. Moreover, using 
the FRAP method, S. ceratophylla exhibited significant 
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antioxidant activity 290.7 μmol  FeSO4 eq/g of dried extract 
[17].
However, the previously obtained results showed that lin-
alool significantly inhibited carrageenin-induced hind paw 
edema (55%, p = 0.03) at a dose of 25 mg/kg [54]. Ma et al. 
[55] reported that the effect of linalool on cigarette smoke 
induced acute lung inflammation and showed that it sup-
pressed the activation of NF-κB in a dose-dependent man-
ner. Hassan et al. [46] showed that α-terpineol inhibited the 
growth of cell lung carcinoma through significant inhibition 
of the NF-κB pathway.
However, in agreement with Gürsoy et al. [3] it is impor-
tant to mention that the anti-oxidative activity of EOs or 
extracts were link with the polarity of their chemical con-
stituents. EOs with non-polar secondary metabolites such as 
terpenoids, were minimally or not active. The anti-inflamma-
tory and radical scavenging activity of S. ceratophylla may 
be ascribe to the high total phenolic contents, thus contribut-
ing to their electron transfer/hydrogen donating capability 
[3, 17, 56].
3.4  Antileishmanial and Antitrypanosomal 
Activities
The present study provided for the first time, data on the 
activity of S. ceratophylla EO and other extracts (from Jor-
dan) against T. brucei and L. donovani in promastigote and 
amastigote stages. Furthermore, this study demonstrated the 
antiprotozoal activity of pure compounds (linalool, α–terpi-
neol and β-caryophyllene).
Table 3  Anti-inflammatory activity of S. ceratophylla essential oil, other extracts and pure compounds
NA Not active at tested concentration
Sample code % decrease in Oxidative stress NO inhibition NF- κB inhibition Sp-1 inhibition
1000 µg/mL 500 µg/mL IC50 (µg/mL) IC50 (µg/mL) IC50 (µg/mL)
EO NA NA 90 38 NA
A 50 47 32 70 70
B 56 25 30 85 160
C 43 29 NA NA NA
D 44 21 40 150 NA
500 µg/mL 250 µg/mL
Linalool NA NA 18 60 NA
Caryophyllene 35 31 NA 45 48
α-Terpineol NA NA NA 100 NA
Quercetin 25 µM 75 – – – –
Parthenolide – – 0.48 0.33 –
Table 4  Antiprotozoal activity of S. ceratophylla essential oil, other extracts and pure compounds (only the antitrypanosomal activity)
NA not active at tested concentration, NT not tested against listed protozoans
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EO and extracts of S. ceratophylla and pure compounds 
did not exhibit antileishmanial activity against extracellu-
lar (promastigote) and intracellular (amastigote) forms of 
L. donovani at all tested concentrations (Table 4). On the 
other hand, the Jordan S. ceratophylla exhibited signifi-
cant antitrypanosomal activity against T. brucei. The EO 
showed higher antitrypanosomal activity with  IC50 and  IC90 
values of 2.65 and 3.61 µg/mL, respectively. The inhibit-
ing activity of the EO was better than that of the control 
(α-difluoromethylornithine) with  IC50 and  IC90 values of 
4.792 and 7.76 µg/mL. Among all extracts, the Ethyl acetate 
extract (B) was the only one that exhibited moderate anti-
trypanosomal activity against T. brucei with  IC50 and  IC90 
values of 15.78 and 19.28 µg/mL, respectively. Among the 
pure compounds, α-terpineol was the only compound that 
exhibited antitrypanosomal activity against T. brucei similar 
to the control (α-difluoromethylornithine) with  IC50 and  IC90 
values of 6.04 and 8.22 µg/mL, respectively.
Interestingly, the results of human acute monocytic leu-
kemia cells toxicity (THP1) showed that the S. ceratophylla 
EO, Ethyl acetate extract (B) and α-terpineol did not exhibit 
cytotoxic effects on mammalian cells at the concentrations 
tested.
Other authors stated that extracts obtained from other Sal-
via species led to similar results than those of S. ceratophylla 
extracts, such as the activity of S. officinalis methanol extract 
from leaves against promastigote and amastigote forms of L. 
major [57]. Moreover, the liquid form of S. officinalis extract 
distributed in the German market did not show remarkable 
antileishmanial activity against L. donovani [21].
Morales et al. [25] studied the antileishmanial activ-
ity of various EO components such as linalool, carvacrol, 
geraniol and terpinen-4-ol against L. infantum promastig-
otes. Accordingly, among the compounds tested, carvacrol 
exhibited the highest activity at the lowest concentration 
of 6.25 µg/mL followed by linalool, which exhibited dose-
dependent antileishmanial activity. At a concentration of 
37.5 µg/mL the inhibitory activity of linalool was similar to 
the control drug (Pentamidine). Moreover, linalool, the main 
EO component of Croton cajucara reduced the viability of 
L. amazonensis promastigotes at very low concentrations 
(MIC, 85.0 pg/ml) and presented no cytotoxic effects against 
mammalian cells [24].
Ślusarczyk et al. [63] showed that among 880 plant and 
fungal extracts, the dichloromethane extract of S. miltio-
rrhiza was the only extract that inhibited 97% of T. bru-
cei rhodesiense growth at the lowest concentration tested 
(0.81 μg/mL). Accordingly, the antitrypanosomal activity 
of S. miltiorrhiza dichloromethane extract was correlate 
with the presence of tanshinone-type diterpenoids, which 
also exhibited antitrypanosomal activity with  IC50 values 
of 0.5 µM to over 30 µM against T. brucei rhodesiense [58].
Both, minor compound (nerolidol) and major compound 
(linalool) of Strychnos spinosa EO demonstrated high and 
selective activity towards Trypanosoma (SI = 35.7 and > 40, 
respectively, and  IC50 = 1.7 and 2.5 µg/mL, respectively). 
α-Terpineol was slightly active against T. brucei bru-
cei blood stream forms [59]. However, these authors also 
reported that the discrepancy in the results might be due to 
different used methods and/or due to differences in stereoi-
someric forms of the compounds tested.
4  Conclusion
The present study revealed that S. ceratophylla EO from Jor-
dan was characterize by a high amount of linalool. Addition-
ally, the EO exhibited significant antitrypanosomal activity 
against T. brucei. Moreover, the inhibitory activity of S. 
ceratophylla EO against T. brucei was stronger than that of 
the control (α-difluoromethylornithine).
This study highlights the potential of this EO as a good 
candidate for the treatment of the hard to cure neglected 
trypanosomiasis infections, also it is demonstrating that S. 
ceratophylla bears promising therapeutic potential for fur-
ther drug development. Importantly, this work also clearly 
validated some of the traditional medicinal uses of Salvia 
species.
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